Ls [36,37]. The biomarker evaluation of the SATURN trial showed no detrimentalLs [36,37]. The biomarker
Ls . The biomarker evaluation of the SATURN trial showed no detrimentalLs . The biomarker analysis of the SATURN trial showed no detrimental impact on PFS with erlotinib in individuals…